Skip to main content

Drug Safety

      Day 4 was a half day closeout to the EULAR 2023 Congress. For me the big presentations were the late breaking abstracts, although there were other review and abstract sessions for those remaining.…
      An update on JAK inhibitors and cardiovascular risks

      Dr. Antoni Chan ( @synovialjoints ) shares #EULAR23 developments
      1 year 6 months ago
      An update on JAK inhibitors and cardiovascular risks Dr. Antoni Chan ( @synovialjoints ) shares #EULAR23 developments on JAK/TYK2 inhibitors. https://t.co/VovWE2OuXW https://t.co/QXKZLh5RuK
      EULAR 2023 Day 4 Recap
      Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias.…
      Upadacitinib in SLE
      Daily Recap: Day Three EULAR 2023
      #EULAR23 – Day 2 Report

      Day 2 at the international EULAR Congress meeting is always bigger and busier. There are mo
      1 year 6 months ago
      #EULAR23 – Day 2 Report Day 2 at the international EULAR Congress meeting is always bigger and busier. There are more sessions to choose from and more audience questions in the big auditorium presentations. https://t.co/vjrG7ez2fX https://t.co/HUuDImzqZA
      ×